P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC

R. Soo,F. De Marinis,J.-Y. Han, C.M.J. Ho, Y. Lin, L. Servidio,M. Sandelin,S. Popat

Journal of Thoracic Oncology(2023)

引用 0|浏览6
暂无评分
关键词
osimertinib,egfr-mutated,ii-iiib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要